<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21312" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Erythromycin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Farzam</surname>
            <given-names>Khashayar</given-names>
          </name>
          <aff>McMaster University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nessel</surname>
            <given-names>Trevor A.</given-names>
          </name>
          <aff>MSU College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Quick</surname>
            <given-names>Judy</given-names>
          </name>
          <aff>Aurora Vista Del Mar</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Khashayar Farzam declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Trevor Nessel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Judy Quick declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21312.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Erythromycin has traditionally been used for various respiratory infections (i.e., community-acquired pneumonia, Legionnaires disease), prophylaxis of neonatal conjunctivitis, and chlamydia. It is also FDA-approved for treating skin infections, intestinal amebiasis, rheumatic fever, prophylaxis, syphilis, and pelvic inflammatory disease (PID). In addition, if mixed with tretinoin cream or benzoyl peroxide, it is effective for treating acne. This activity will highlight the mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of erythromycin, other key factors (e.g., dosing, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the interprofessional team in the treatment of patients with infections and other conditions where this agent is indicated.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the mechanism of antibacterial action for erythromycin.</p></list-item><list-item><p>Outline the infectious and non-infectious indications for erythromycin.</p></list-item><list-item><p>Review the potential adverse events associated with erythromycin.</p></list-item><list-item><p>Explain the importance of improving care coordination among the interprofessional team to enhance the delivery of care for patients when using erythromycin.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21312&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21312">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21312.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Erythromycin is a macrolide antibiotic initially discovered in 1952. It&#x000a0;is useful for treating various infections and also has an indication for a non-infectious pathology.</p>
        <p>Traditionally, its use has been for various respiratory infections (i.e., community-acquired pneumonia, Legionnaires disease),&#x000a0;prophylaxis of neonatal conjunctivitis, and chlamydia.<xref ref-type="bibr" rid="article-21312.r1">[1]</xref>&#x000a0;It is also FDA-approved for treating&#x000a0;skin infections, intestinal amebiasis, rheumatic fever, prophylaxis, syphilis, and&#x000a0;pelvic inflammatory disease (PID).<xref ref-type="bibr" rid="article-21312.r2">[2]</xref> If mixed with tretinoin cream or benzoyl peroxide, it is effective for treating acne.<xref ref-type="bibr" rid="article-21312.r3">[3]</xref>&#x000a0;During pregnancy, clinicians can use it to prevent Group B streptococcal infection in the newborn.<xref ref-type="bibr" rid="article-21312.r4">[4]</xref>&#x000a0;</p>
        <p>Erythromycin&#x000a0;is also used off-label for treating gastroparesis, also known as delayed gastric emptying. However, the treatment of gastroparesis is a non-FDA-approved indication.<xref ref-type="bibr" rid="article-21312.r5">[5]</xref></p>
      </sec>
      <sec id="article-21312.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Erythromycin is a bacteriostatic antibiotic, which means it prevents the further growth of bacteria rather than directly destroying them. This action occurs by inhibiting protein synthesis. Erythromycin binds to the 23S ribosomal RNA molecule in the 50S subunit of the bacterial ribosome; this causes a blockage in&#x000a0;peptide chain synthesis, ultimately inhibiting the protein synthesis.&#x000a0;Humans have the 40S and 60S subunits and do not have 50S subunits, so erythromycin does not affect protein synthesis in human tissues.<xref ref-type="bibr" rid="article-21312.r6">[6]</xref><xref ref-type="bibr" rid="article-21312.r7">[7]</xref></p>
        <p>Macrolide antibiotics have anti-inflammatory and immunomodulatory actions. In preclinical studies, erythromycin inhibited neutrophil infiltration in the lungs and the periodontium. As a result, erythromycin protected against fatal pulmonary inflammation and inflammatory periodontal bone loss. Furthermore, because developmental endothelial locus-1 (DEL-1) levels are severely reduced in inflammatory conditions and aging, erythromycin's ability to upregulate DEL-1 may reveal a novel molecular mechanism responsible for erythromycin's anti-inflammatory and immunomodulatory actions.<xref ref-type="bibr" rid="article-21312.r8">[8]</xref></p>
        <p>Erythromycin is active against gram-positive bacteria, gram-negative bacteria, and&#x000a0;several other organisms. The gram-positive bacteria include&#x000a0;<italic toggle="yes">Streptococcus pneumoniae</italic>,&#x000a0;<italic toggle="yes">Streptococcus pyogenes</italic>,&#x000a0;<italic toggle="yes">Staphylococcus aureus</italic>,&#x000a0;<italic toggle="yes">Listeria monocytogenes</italic>,&#x000a0;<italic toggle="yes">Corynebacterium minutissimum</italic>,&#x000a0;<italic toggle="yes">Corynebacterium diphtheria</italic>. The gram-negative bacteria include&#x000a0;<italic toggle="yes">Legionella pneumophila</italic>,&#x000a0;<italic toggle="yes">Neisseria gonorrhoeae</italic>,&#x000a0;<italic toggle="yes">Haemophilus influenzae</italic>, and&#x000a0;<italic toggle="yes">Bordetella pertussis</italic>. Other microorganisms covered by erythromycin include&#x000a0;<italic toggle="yes">Chlamydia trachomatis</italic>,&#x000a0;<italic toggle="yes">Entamoeba histolytica</italic>,&#x000a0;<italic toggle="yes">Mycoplasma pneumoniae</italic>,&#x000a0;<italic toggle="yes">Treponema pallidum</italic>, and&#x000a0;<italic toggle="yes">Ureaplasma urealyticum</italic>.<xref ref-type="bibr" rid="article-21312.r2">[2]</xref></p>
        <p>Resistance can develop against erythromycin; this occurs via modification of the 23S rRNA found in the 50S rRNA. The erythromycin cannot bind to the ribosome, and the bacteria can continue protein synthesis.<xref ref-type="bibr" rid="article-21312.r9">[9]</xref><xref ref-type="bibr" rid="article-21312.r10">[10]</xref>&#x000a0;Aside from being a bacteriostatic macrolide antibiotic, erythromycin&#x000a0;is a pro-motility drug. It is an agonist to motilin, which increases motility in the gut.<xref ref-type="bibr" rid="article-21312.r11">[11]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption: </bold>As erythromycin&#x000a0;gets deactivated&#x000a0;by gastric acid, oral tablets must either contain an ester or stable salt as part of the molecular structure or be enteric-coated. Once erythromycin is orally administered, it is easily absorbed through the gastrointestinal system.&#x000a0;It diffuses into various tissues and phagocytes following absorption via the gastrointestinal system. As phagocytes circulate in the blood and induce phagocytosis of harmful bacteria, erythromycin gets released during this process.&#x000a0;Optimal blood levels are reached when&#x000a0;the patient takes it in a fasting state. Peak plasma concentration (Cmax) is achieved in four hours when administered with food.<xref ref-type="bibr" rid="article-21312.r12">[12]</xref></p>
        <p><bold>Distribution: </bold>Erythromycin is largely bound to plasma proteins, but erythromycin&#x000a0;readily diffuses into most bodily fluids. Erythromycin is concentrated in the liver and is later excreted&#x000a0;in bile.</p>
        <p><bold>Metabolism:&#x000a0;</bold>The liver metabolizes most of the administered erythromycin. It undergoes demethylation through the cytochrome P450 system, specifically the enzyme CYP3A4.</p>
        <p><bold>Excretion:&#x000a0;&#x000a0;</bold>Erythromycin is mostly excreted&#x000a0;through bile. A tiny percentage of the drug undergoes renal excretion. Erythromycin has a half-life of 1.5&#x000a0;hours to 2 hours.&#x000a0;Optimal blood levels are reached when&#x000a0;the patient takes it in a fasting state. Peak plasma concentration(Cmax) is achieved in four hours when administered with food.</p>
      </sec>
      <sec id="article-21312.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Routes of Administration</bold>
</p>
        <p>Erythromycin base filmtab tablets (erythromycin tablets, USP) are supplied as pink, unscored oval tablets. Erythromycin&#x000a0;can also be administered intravenous, topical, and ophthalmic routes.</p>
        <p>
<bold>Adults</bold>
</p>
        <p>The oral form of the medication is available in 250 mg tablets and 500 mg tablets. For maximal absorption and minimal side effects, the patient should avoid alcohol, take the drug on an empty stomach (1 hour before or 2 hours after meals), take a full glass of water, and avoid grapefruit juice.<xref ref-type="bibr" rid="article-21312.r13">[13]</xref>&#x000a0;The maximum recommended oral dose is 4 grams per day.&#x000a0;</p>
        <p>
<bold>Children</bold>
</p>
        <p>The usual dosage for children is 30 to 50 mg/kg/day in equally divided doses. The maximum recommended dosage is 4 grams per day for more severe infections.</p>
        <p>
<bold>Pregnancy</bold>
</p>
        <p>For urogenital infections during pregnancy, the recommended dose is&#x000a0;500 mg of erythromycin by mouth four times a day on an empty stomach for at least seven&#x000a0;days.<xref ref-type="bibr" rid="article-21312.r14">[14]</xref></p>
        <p>
<bold>Specific Patient Population</bold>
</p>
        <p><bold>Patients with Renal Impairment: </bold>The manufacturer's labeling has provided no information regarding adult patients with renal impairment. However, elderly patients with reduced renal function may be at increased risk for ototoxicity.</p>
        <p><bold>Patients with Hepatic Impairment: </bold>No information has been provided in the manufacturer's labeling. However, clinicians should prescribe erythromycin with caution, given the hepatotoxic potential of erythromycin.<xref ref-type="bibr" rid="article-21312.r15">[15]</xref></p>
        <p><bold>Pregnancy Considerations:&#x000a0;</bold>According to the manufacturer's labeling, there is no evidence of teratogenicity or other adverse effects on reproduction in female rats administered erythromycin, approximately twice the maximum recommended human dose (MRHD) based on a body surface area.&#x000a0;</p>
        <p><bold>Breastfeeding Considerations: </bold>Erythromycin is excreted in human milk, and the small amounts in milk are unlikely to cause adverse effects in the infant. Monitor the infant for irritability and possible effects on the gastrointestinal flora, such as diarrhea and candidiasis (thrush, diaper rash). One case report and epidemiological evidence indicate hypertrophic pyloric stenosis in infants.<xref ref-type="bibr" rid="article-21312.r16">[16]</xref>&#x000a0;According to a meta-analysis, using erythromycin in the first two weeks of life is associated with the risk of pyloric stenosis. However, there is no definitive evidence of a significant association between macrolide use during pregnancy or breastfeeding and pyloric stenosis.<xref ref-type="bibr" rid="article-21312.r17">[17]</xref>&#x000a0;Erythromycin is used to treat pertussis or neonatal Chlamydia trachomatis infections in infants; hence the benefit of erythromycin treatment must be considered against the potential risk of developing pyloric stenosis.</p>
      </sec>
      <sec id="article-21312.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>It may also increase the risk of pyloric stenosis in the newborn. All antibiotics carry a significant risk of nausea, vomiting, abdominal pain, and diarrhea. Erythromycin is a motilin agonist, which increases the likelihood of gastrointestinal side effects compared to other antibiotics.<xref ref-type="bibr" rid="article-21312.r18">[18]</xref>&#x000a0;All macrolide antibiotics cause QT prolongation. Azithromycin&#x000a0;causes clinically insignificant&#x000a0;QT prolongation. Clarithromycin&#x000a0;causes greater QT prolongation. Erythromycin&#x000a0;is known&#x000a0;to cause significant prolongation of the QT interval and carries a risk of torsades de pointes.<xref ref-type="bibr" rid="article-21312.r19">[19]</xref> This arrhythmia may cease on its own or may degenerate into ventricular fibrillation, which can be fatal.<xref ref-type="bibr" rid="article-21312.r20">[20]</xref>&#x000a0;There also exists a risk of rash, allergic reaction, and reversible deafness. Rare side effects include Stevens-Johnson syndrome and toxic epidermal necrolysis.<xref ref-type="bibr" rid="article-21312.r21">[21]</xref>&#x000a0;</p>
        <p>Erythromycin is a cytochrome P-450 inhibitor; this means it carries the potential to interact with a broad range of medications. Given it is an inhibitor of cytochrome P-450, drugs that get metabolized&#x000a0;via the cytochrome P-450 system would have increased concentrations, leading to an increased risk of toxicity.<xref ref-type="bibr" rid="article-21312.r22">[22]</xref></p>
        <p>Initially, hepatotoxicity was thought to be more common with erythromycin estolate. However, case reports of jaundice and liver damage have been documented in all formulations of erythromycin.&#x000a0;Most cases of erythromycin-induced liver disease are self-limiting; however, rare instances of severe acute hepatic injury leading to acute liver failure and the need for transplantation have been reported. Furthermore, isolated examples of prolonged cholestasis with vanishing bile duct syndrome have been reported. Therefore, patients with erythromycin-induced hepatic injury should be cautioned to avoid further exposure. In addition, it is prudent to avoid using other macrolides in patients with clinically apparent liver injury due to erythromycin.<xref ref-type="bibr" rid="article-21312.r15">[15]</xref></p>
      </sec>
      <sec id="article-21312.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Erythromycin is contraindicated in patients with known hypersensitivity to this drug. In addition, as erythromycin may cause serious rashes in a small number of patients, anyone who has experienced similar symptoms in the past should avoid future use of the drug.&#x000a0;Due to the increased risk of myopathy, do not use erythromycin with HMG CoA reductase inhibitors (statins) that are metabolized by CYP3A4 (simvastatin or lovastatin).</p>
        <p>Patients with a prolonged QT interval on an electrocardiogram (ECG) should not use erythromycin. A normal QTc interval would be less than 440 ms in males and less than 460 ms in females. Anyone using a medication that prolongs the QT interval should be very&#x000a0;cautious and monitor if adding erythromycin. Similarly, patients with long QT syndrome (LQTS) should not use erythromycin. Patients who have had a past medical history of episodes of torsades de pointes should avoid QT-prolonging drugs such as erythromycin. Erythromycin is contraindicated in patients taking terfenadine, astemizole, or cisapride.<xref ref-type="bibr" rid="article-21312.r19">[19]</xref></p>
      </sec>
      <sec id="article-21312.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Erythromycin has significant&#x000a0;promotility activity and is used in patients with gastroparesis. The clinician should monitor the&#x000a0;development of microbial resistance to erythromycin following its long-term use as a promotility agent. Liver function tests require monitoring because of the potential for rare but serious hepatic failure.<xref ref-type="bibr" rid="article-21312.r23">[23]</xref>&#x000a0;QT interval prolongation is a possible adverse effect and requires careful vigilance in patients with heart conditions or who take antiarrhythmic or interacting drugs.&#x000a0;Pseudomembranous colitis has been reported with erythromycin and may range in severity from mild to life-threatening; the&#x000a0;clinician should consider this diagnosis in patients with severe diarrhea after its administration.<xref ref-type="bibr" rid="article-21312.r24">[24]</xref></p>
      </sec>
      <sec id="article-21312.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Macrolide&#x000a0;antibiotics have varying levels of cardiotoxicity. Erythromycin carries the most prominent risk of cardiotoxicity among the more commonly used macrolide antibiotics. It induces&#x000a0;QT&#x000a0;prolongation and&#x000a0;increases the risk of the potentially deadly heart rhythm known as torsades de&#x000a0;pointes. Careful monitoring of the&#x000a0;QTc&#x000a0;interval on the&#x000a0;EKG is recommended to minimize risk. Clinicians should monitor&#x000a0;potassium, magnesium, and calcium levels in high-risk patients.&#x000a0;There is no known reversal agent for erythromycin.<xref ref-type="bibr" rid="article-21312.r19">[19]</xref></p>
      </sec>
      <sec id="article-21312.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Erythromycin causes common adverse drug reactions such as nausea, vomiting, diarrhea, and serious adverse drug reactions such as QT prolongation and pseudomembranous colitis. The clinician who is prescribing erythromycin should&#x000a0;monitor the patient for QT prolongation. Torsades de&#x000a0;pointes require the immediate cessation of therapy, referral to a cardiologist, and prompt treatment. Pseudomembranous colitis requires referral to a gastroenterologist. Pharmacists should check for potential drug-drug interactions as erythromycin is a known enzyme inhibitor. Pharmacists should also ensure proper medication reconciliation. The nurses can play a vital role in medication administration and patient education.</p>
        <p>The Core Elements of Antibiotic Stewardship compromise a framework for improving antibiotic prescribing, including macrolides, for individual clinicians and healthcare organizations. Prescribing erythromycin for labeled indications can significantly improve antibiotic resistance and optimally uses an interprofessional team approach.<xref ref-type="bibr" rid="article-21312.r25">[25]</xref>&#x000a0;Any interprofessional team member who encounters any issues with therapy, including adverse events or signs of therapeutic failure, must immediately note their findings in the patient health record and report this information to other team members to take corrective action. The interprofessional team approach that includes clinicians, specialists, nurses, and pharmacists, would maximize therapeutic efficacy, minimize the risk of adverse drug reactions and antibiotic resistance, and&#x000a0;ultimately achieve&#x000a0;the best possible patient outcome. [Level 5]</p>
      </sec>
      <sec id="article-21312.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21312&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21312">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21312/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21312">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21312.s11">
        <title>References</title>
        <ref id="article-21312.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marchant</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Petsky</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Antibiotics for prolonged wet cough in children.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2018</year>
            <month>Jul</month>
            <day>31</day>
            <volume>7</volume>
            <issue>7</issue>
            <fpage>CD004822</fpage>
            <pub-id pub-id-type="pmid">30062732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21312.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amsden</surname>
                <given-names>GW</given-names>
              </name>
            </person-group>
            <article-title>Erythromycin, clarithromycin, and azithromycin: are the differences real?</article-title>
            <source>Clin Ther</source>
            <year>1996</year>
            <season>Jan-Feb</season>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>56</fpage>
            <page-range>56-72; discussion 55</page-range>
            <pub-id pub-id-type="pmid">8851453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21312.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmidt</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gans</surname>
                <given-names>EH</given-names>
              </name>
            </person-group>
            <article-title>Tretinoin: A Review of Its Anti-inflammatory Properties in the Treatment of Acne.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>4</volume>
            <issue>11</issue>
            <fpage>22</fpage>
            <page-range>22-9</page-range>
            <pub-id pub-id-type="pmid">22125655</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21312.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Morgan</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Zafar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <chapter-title>Group B Streptococcus and Pregnancy</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">29494050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21312.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Camilleri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Parkman</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Shafi</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Abell</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Gerson</surname>
                <given-names>L</given-names>
              </name>
              <collab>American College of Gastroenterology</collab>
            </person-group>
            <article-title>Clinical guideline: management of gastroparesis.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>108</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-37; quiz 38</page-range>
            <pub-id pub-id-type="pmid">23147521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21312.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tenson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lovmar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ehrenberg</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome.</article-title>
            <source>J Mol Biol</source>
            <year>2003</year>
            <month>Jul</month>
            <day>25</day>
            <volume>330</volume>
            <issue>5</issue>
            <fpage>1005</fpage>
            <page-range>1005-14</page-range>
            <pub-id pub-id-type="pmid">12860123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21312.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Structure-activity relationships and mechanism of action of macrolides derived from erythromycin as antibacterial agents.</article-title>
            <source>Curr Top Med Chem</source>
            <year>2013</year>
            <volume>13</volume>
            <issue>24</issue>
            <fpage>3131</fpage>
            <page-range>3131-64</page-range>
            <pub-id pub-id-type="pmid">24200358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21312.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maekawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Domon</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hiyoshi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Isono</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yonezawa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tabeta</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Maeda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Oda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ziogas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alexaki</surname>
                <given-names>VI</given-names>
              </name>
              <name>
                <surname>Chavakis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Terao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hajishengallis</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Erythromycin inhibits neutrophilic inflammation and mucosal disease by upregulating DEL-1.</article-title>
            <source>JCI Insight</source>
            <year>2020</year>
            <month>Aug</month>
            <day>06</day>
            <volume>5</volume>
            <issue>15</issue>
            <pub-id pub-id-type="pmid">32603314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21312.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guo</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>QB</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Insights into the amplification of bacterial resistance to erythromycin in activated sludge.</article-title>
            <source>Chemosphere</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>136</volume>
            <fpage>79</fpage>
            <page-range>79-85</page-range>
            <pub-id pub-id-type="pmid">25957255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21312.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varaldo</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Montanari</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Giovanetti</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Genetic elements responsible for erythromycin resistance in streptococci.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>53</volume>
            <issue>2</issue>
            <fpage>343</fpage>
            <page-range>343-53</page-range>
            <pub-id pub-id-type="pmid">19001115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21312.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maganti</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Onyemere</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Oral erythromycin and symptomatic relief of gastroparesis: a systematic review.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2003</year>
            <month>Feb</month>
            <volume>98</volume>
            <issue>2</issue>
            <fpage>259</fpage>
            <page-range>259-63</page-range>
            <pub-id pub-id-type="pmid">12591038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21312.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Albarellos</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Montoya</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Landoni</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of erythromycin after intravenous, intramuscular and oral administration to cats.</article-title>
            <source>Vet J</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>187</volume>
            <issue>1</issue>
            <fpage>129</fpage>
            <page-range>129-32</page-range>
            <pub-id pub-id-type="pmid">19854664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21312.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis.</article-title>
            <source>Pediatr Infect Dis J</source>
            <year>1992</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>12</issue>
            <fpage>1026</fpage>
            <page-range>1026-30</page-range>
            <pub-id pub-id-type="pmid">1461692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21312.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cluver</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Novikova</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Eriksson</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Bengtsson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lingman</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>Interventions for treating genital Chlamydia trachomatis infection in pregnancy.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>Sep</month>
            <day>22</day>
            <volume>9</volume>
            <issue>9</issue>
            <fpage>CD010485</fpage>
            <pub-id pub-id-type="pmid">28937705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21312.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <chapter-title>Erythromycin</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>8</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">31643217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21312.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <chapter-title>Erythromycin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2019</year>
            <month>4</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">30000276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21312.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdellatif</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ghozy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kamel</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Elawady</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Ghorab</surname>
                <given-names>MME</given-names>
              </name>
              <name>
                <surname>Attia</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Le Huyen</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Duy</surname>
                <given-names>DTV</given-names>
              </name>
              <name>
                <surname>Hirayama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Huy</surname>
                <given-names>NT</given-names>
              </name>
            </person-group>
            <article-title>Association between exposure to macrolides and the development of infantile hypertrophic pyloric stenosis: a systematic review and meta-analysis.</article-title>
            <source>Eur J Pediatr</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>178</volume>
            <issue>3</issue>
            <fpage>301</fpage>
            <page-range>301-314</page-range>
            <pub-id pub-id-type="pmid">30470884</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21312.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carter</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Woodhead</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Milavetz</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Gastrointestinal side effects with erythromycin preparations.</article-title>
            <source>Drug Intell Clin Pharm</source>
            <year>1987</year>
            <month>Sep</month>
            <volume>21</volume>
            <issue>9</issue>
            <fpage>734</fpage>
            <page-range>734-8</page-range>
            <pub-id pub-id-type="pmid">3498618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21312.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hancox</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Hasnain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vieweg</surname>
                <given-names>WV</given-names>
              </name>
              <name>
                <surname>Gysel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Methot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baranchuk</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Erythromycin, QTc interval prolongation, and torsade de pointes: Case reports, major risk factors and illness severity.</article-title>
            <source>Ther Adv Infect Dis</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>47</fpage>
            <page-range>47-59</page-range>
            <pub-id pub-id-type="pmid">25165555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21312.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Macrolides use and the risk of sudden cardiac death.</article-title>
            <source>Expert Rev Anti Infect Ther</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>535</fpage>
            <page-range>535-7</page-range>
            <pub-id pub-id-type="pmid">27086751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21312.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Stevens-Johnson syndrome after erythromycin therapy while deployed at sea.</article-title>
            <source>Mil Med</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>165</volume>
            <issue>8</issue>
            <fpage>636</fpage>
            <page-range>636-7</page-range>
            <pub-id pub-id-type="pmid">10957862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21312.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akiyoshi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Murase</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miyazaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guengerich</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ohtani</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Mechanism-based inhibition profiles of erythromycin and clarithromycin with cytochrome P450 3A4 genetic variants.</article-title>
            <source>Drug Metab Pharmacokinet</source>
            <year>2013</year>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>411</fpage>
            <page-range>411-5</page-range>
            <pub-id pub-id-type="pmid">23514827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21312.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andrade</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Tulkens</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Hepatic safety of antibiotics used in primary care.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>66</volume>
            <issue>7</issue>
            <fpage>1431</fpage>
            <page-range>1431-46</page-range>
            <pub-id pub-id-type="pmid">21586591</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21312.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghoshal</surname>
                <given-names>UC</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapy for gastroparesis: an attempt to evaluate a safer alternative.</article-title>
            <source>J Neurogastroenterol Motil</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>350</fpage>
            <page-range>350-2</page-range>
            <pub-id pub-id-type="pmid">21103416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21312.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanchez</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Hersh</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Fleming-Dutra</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Outpatient Macrolide Antibiotic Prescribing in the United States, 2008-2011.</article-title>
            <source>Open Forum Infect Dis</source>
            <year>2017</year>
            <season>Fall</season>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>ofx220</fpage>
            <pub-id pub-id-type="pmid">29255725</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
